Trius Therapeutics Inc (TSRX.OQ)

TSRX.OQ on NASDAQ Stock Exchange Global Market

13.81USD
1:15pm EDT
Price Change (% chg)

$-0.29 (-2.09%)
Prev Close
$14.10
Open
$13.80
Day's High
$13.89
Day's Low
$13.75
Volume
273,626
Avg. Vol
328,056
52-wk High
$14.16
52-wk Low
$4.41

TSRX.OQ

Chart for TSRX.OQ

About

Trius Therapeutics, Inc. operates as a biopharmaceutical research company. It has a cooperative research and development agreement with Lawrence Livermore National Security LLC for the research and development of gram-negative biodefense pathogens; and a license agreement with Dong-A Pharmaceutical Co., Ltd. to develop and sell... (more)

Overall

Beta: --
Market Cap (Mil.): $675.00
Shares Outstanding (Mil.): 47.87
Dividend: --
Yield (%): --

Financials

  TSRX.OQ Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -1.56 -- --
ROI: -77.67 19.48 18.76
ROE: -77.67 20.17 19.59
Search Stocks

Cubist to pay up to $1.6 billion for two antibiotics makers

- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.

30 Jul 2013

UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers

* Cubist sees the sum of both deals to be accretive in 2015

30 Jul 2013

Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion

- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.

30 Jul 2013

CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln

(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)

30 Jul 2013

BRIEF-Trius Therapeutics up in premarket after tedizolid study results

NEW YORK, March 25 - Trius Therapeutics Inc : * Up 6.6 percent to $7.45 in premarket after tedizolid study results

25 Mar 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks